Innovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients#China#Suzhou#Multiple_Myeloma#Innovent#IBI3003
Innovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients
Innovent Biologics presents updated data for IBI3003, a novel trispecific antibody for relapsed multiple myeloma, demonstrating significant efficacy with an 84.6% overall response rate in Phase 1 trials.
third-news.com
September 29, 2026 at 7:48 AM
Innovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients#China#Suzhou#Multiple_Myeloma#Innovent#IBI3003
Jing Li, MD, shares updated data for IBI3003, a novel BCMA×GPRC5d×CD3 trispecific antibody, in triple drug class-exposed pts with relapsed/refractory myeloma. ORR was 80%–85%, w/ 100% MRD-negativity, & efficacy also in pts w/ prior BCMA tx. #IMS26
September 26, 2026 at 11:16 AM
Jing Li, MD, shares updated data for IBI3003, a novel BCMA×GPRC5d×CD3 trispecific antibody, in triple drug class-exposed pts with relapsed/refractory myeloma. ORR was 80%–85%, w/ 100% MRD-negativity, & efficacy also in pts w/ prior BCMA tx. #IMS26
Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment#United_States#San_Francisco#Multiple_Myeloma#Innovent#IBI3003
Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment
The FDA has granted Innovent's IBI3003 Fast Track Designation for treating relapsed multiple myeloma, enhancing development and approval speeds.
third-news.com
January 27, 2026 at 12:10 AM
Innovent's IBI3003 Antibody Gains Fast Track Status for Multiple Myeloma Treatment#United_States#San_Francisco#Multiple_Myeloma#Innovent#IBI3003
FDA grants Fast Track designation to IBI3003, a trispecific antibody for relapsed or refractory multiple myeloma. FDA Fast Track Designation helps speed the development and review of treatments for serious conditions with unmet needs. Learn more: https://mmsm.link/3ZCKQoB
February 4, 2026 at 3:29 PM
FDA grants Fast Track designation to IBI3003, a trispecific antibody for relapsed or refractory multiple myeloma. FDA Fast Track Designation helps speed the development and review of treatments for serious conditions with unmet needs. Learn more: https://mmsm.link/3ZCKQoB
But I am now reading there are TRI specific antibodies being investigated, the immunological side of this is FASCINATING. I am reading Song of the Cell Siddharta Mukherjee at Columbia, using immune cells against cancer gives patients HOPE - www.cancernetwork.com/view/trispec...
Trispecific Antibody Earns FDA Fast Track Designation in Multiple Myeloma | CancerNetwork
Investigators are currently assessing IBI3003 among patients with relapsed/refractory multiple myeloma in a phase 1/2 trial.
www.cancernetwork.com
March 29, 2026 at 1:03 AM
But I am now reading there are TRI specific antibodies being investigated, the immunological side of this is FASCINATING. I am reading Song of the Cell Siddharta Mukherjee at Columbia, using immune cells against cancer gives patients HOPE - www.cancernetwork.com/view/trispec...
[2/2] developed innovative anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003 has completed the first subject administration of China's pivotal Phase III clinical study (TriadicMM-1) for the treatment of second- to fifth-line multiple myeloma (R/R MM).
June 22, 2026 at 12:52 AM
[2/2] developed innovative anti-GPRC5D/BCMA/CD3 trispecific antibody IBI3003 has completed the first subject administration of China's pivotal Phase III clinical study (TriadicMM-1) for the treatment of second- to fifth-line multiple myeloma (R/R MM).
[1/2] 2026-06-22 08:43:51 - [Innovent: China's pivotal Phase III clinical study of IBI3003 for the treatment of second- to fifth-line multiple myeloma has completed the first subject administration] On June 22, Innovent Biopharmaceutical Group announced that its independently
June 22, 2026 at 12:52 AM
[1/2] 2026-06-22 08:43:51 - [Innovent: China's pivotal Phase III clinical study of IBI3003 for the treatment of second- to fifth-line multiple myeloma has completed the first subject administration] On June 22, Innovent Biopharmaceutical Group announced that its independently
Innovent Biologics Initiates Phase 3 Trial of IBI3003 for Multiple Myeloma Treatment#China#Suzhou#Innovent_Biologics#Multiple_Myeloma#IBI3003
Innovent Biologics Initiates Phase 3 Trial of IBI3003 for Multiple Myeloma Treatment
Innovent Biologics has commenced a Phase 3 clinical trial for IBI3003, a novel tri-specific antibody for treating relapsed multiple myeloma. This is a significant advancement in immunotherapy.
third-news.com
June 22, 2026 at 12:11 AM
Innovent Biologics Initiates Phase 3 Trial of IBI3003 for Multiple Myeloma Treatment#China#Suzhou#Innovent_Biologics#Multiple_Myeloma#IBI3003
Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma#China#Suzhou#Multiple_Myeloma#Innovent#IBI3003
Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma
Innovent Biologics presents initial findings from its first-in-human trial of the trispecific antibody IBI3003 for relapsed multiple myeloma at ASH 2025.
third-news.com
December 8, 2025 at 1:11 AM
Innovent Biologics Reveals Promising Initial Results for IBI3003 in Treating Multiple Myeloma#China#Suzhou#Multiple_Myeloma#Innovent#IBI3003
